This month, we are focusing on Oncology and have reflected on the notable advancements to oncology medications in recent years. Immunotherapy: Immunotherapy has been a significant focus in oncology. Checkpoint inhibitors, such as pembrolizumab and nivolumab have shown success in treating various cancers by targeting specific proteins that inhibit the immune system's response to cancer cells. CSI has longstanding experience sourcing these immunotherapy drugs for over 100 studi

How CSI supplied large quantities of ruxolitinib to a biotech’s ongoing Phase 3 oncology study involving 14 countries, nine depots and 67 site shipments Challenge CSI was approached by a biotech conducting a full global Phase 3 oncology study spanning 14 countries. We were asked to purchase and supply a significant quantity of ruxolitinib within a tight timeframe: with the contract signed in December 2022, the client aimed to have the first sites supplied by March 2023. The